MY190889A - Antibodies directed against cd127 - Google Patents

Antibodies directed against cd127

Info

Publication number
MY190889A
MY190889A MYPI2016002094A MYPI2016002094A MY190889A MY 190889 A MY190889 A MY 190889A MY PI2016002094 A MYPI2016002094 A MY PI2016002094A MY PI2016002094 A MYPI2016002094 A MY PI2016002094A MY 190889 A MY190889 A MY 190889A
Authority
MY
Malaysia
Prior art keywords
seq
antibodies
site
sequence
epitope
Prior art date
Application number
MYPI2016002094A
Other languages
English (en)
Inventor
Nicolas Poirier
Caroline Mary
Bernard Vanhove
Original Assignee
Ose Immunotherapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52434718&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY190889(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ose Immunotherapeutics filed Critical Ose Immunotherapeutics
Publication of MY190889A publication Critical patent/MY190889A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5418—IL-7
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70546—Integrin superfamily, e.g. VLAs, leuCAM, GPIIb/GPIIIa, LPAM
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7155—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Emergency Medicine (AREA)
MYPI2016002094A 2014-06-10 2015-06-10 Antibodies directed against cd127 MY190889A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462010117P 2014-06-10 2014-06-10
EP15305078.6A EP2955196A1 (en) 2014-06-10 2015-01-23 Antibodies directed against CD127
PCT/EP2015/062993 WO2015189302A1 (en) 2014-06-10 2015-06-10 Antibodies directed against cd127

Publications (1)

Publication Number Publication Date
MY190889A true MY190889A (en) 2022-05-17

Family

ID=52434718

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2016002094A MY190889A (en) 2014-06-10 2015-06-10 Antibodies directed against cd127

Country Status (26)

Country Link
US (3) US10428152B2 (enExample)
EP (2) EP2955196A1 (enExample)
JP (2) JP7324565B2 (enExample)
KR (1) KR102612930B1 (enExample)
CN (1) CN106715471B (enExample)
AP (1) AP2016009599A0 (enExample)
AU (1) AU2015273532C1 (enExample)
BR (1) BR112016028755B1 (enExample)
CA (1) CA2950823A1 (enExample)
CL (1) CL2016003172A1 (enExample)
CR (1) CR20160576A (enExample)
EA (1) EA039303B1 (enExample)
HK (1) HK1231487A1 (enExample)
IL (1) IL249449B (enExample)
MA (1) MA40202A (enExample)
MX (1) MX376066B (enExample)
MY (1) MY190889A (enExample)
NZ (1) NZ726932A (enExample)
PE (1) PE20170324A1 (enExample)
PH (1) PH12016502445A1 (enExample)
RU (1) RU2734076C2 (enExample)
SA (1) SA516380455B1 (enExample)
SG (1) SG11201610036PA (enExample)
TN (1) TN2016000528A1 (enExample)
UA (1) UA125366C2 (enExample)
WO (1) WO2015189302A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201606970UA (en) 2012-02-23 2016-10-28 Juno Therapeutics Gmbh Chromatographic isolation of cells and other complex biological materials
EP2955196A1 (en) * 2014-06-10 2015-12-16 Effimune Antibodies directed against CD127
CA2981098A1 (en) 2015-03-31 2016-10-06 Vhsquared Limited Peptide construct having a protease-cleavable linker
CA2981103A1 (en) 2015-03-31 2016-10-06 Vhsquared Limited Polypeptides
MA45488A (fr) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh Procédés, kits et appareil de culture de cellules
EP3405491A1 (en) 2016-01-21 2018-11-28 VHsquared Limited Polypeptides
PT3423496T (pt) 2016-02-29 2019-09-05 Ose Immunotherapeutics Anticorpos não antagonistas dirigidos contra a cadeia alfa do domínio extracelular do recetor da il-7 e a utilização do mesmo no tratamento do cancro
EA201991005A1 (ru) * 2016-12-09 2019-12-30 Осе Иммьюнотерапьютикс Антитела и полипептиды, направленные против cd127
WO2019043065A1 (en) * 2017-08-29 2019-03-07 Ose Immunotherapeutics METHOD AND PREPARATION FOR SORTING T EFFECTOR LYMPHOCYTES USING ANTI-CD127 ANTIBODIES FOR CELL THERAPY APPLICATIONS
CN110117325B (zh) * 2018-03-09 2023-06-20 重庆市畜牧科学院 一种猪cd127多肽及其编码基因和应用
KR102570405B1 (ko) 2019-01-22 2023-08-25 브리스톨-마이어스 스큅 컴퍼니 Il-7r 알파 서브유닛에 대한 항체 및 이의 용도
KR102503349B1 (ko) 2019-05-14 2023-02-23 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
AU2020294980A1 (en) 2019-06-21 2022-02-17 Sorriso Pharmaceuticals, Inc. Polypeptides
CN114555643B (zh) 2019-06-21 2025-02-18 索瑞索制药公司 组合物
CN119684455A (zh) 2019-06-21 2025-03-25 索瑞索制药公司 多肽
CN110894237B (zh) * 2019-12-05 2021-08-03 山东省分析测试中心 抗cd127的抗体、分泌该抗体的细胞株及其制备方法和应用
AU2021262748A1 (en) * 2020-04-27 2022-12-01 Memorial Sloan-Kettering Cancer Center Chimeric antigen receptors targeting CD127 and use thereof
IL298999A (en) 2020-06-11 2023-02-01 Provention Bio Inc Methods and compositions for the prevention of type 1 diabetes
US20220389104A1 (en) 2021-05-28 2022-12-08 Ose Immunotherapeutics Method for Treating CD127-Positive Cancers by Administering an Anti-CD127 Agent
JP2025518164A (ja) 2022-05-30 2025-06-12 オセ イムノセラピューティクス Ｉｌ７ｒモジュレーター活性のバイオマーカー
CN115925955B (zh) * 2022-12-30 2025-09-26 浙江正熙生物技术有限公司 一种抗cd127抗体及其制备方法和应用
CN121002069A (zh) 2023-01-06 2025-11-21 泰温治疗私人有限公司 抗原结合分子
EP4455308A1 (en) 2023-04-24 2024-10-30 Les Laboratoires Servier Il-7r gene signatures
US12311033B2 (en) 2023-05-31 2025-05-27 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
WO2025076127A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025089399A1 (ja) * 2023-10-26 2025-05-01 国立研究開発法人国立がん研究センター インターロイキン７受容体（ｉｌ－７ｒ）に対する抗体および当該抗体を含む抗体薬物コンジュゲート（ａｄｃ）
US20250302763A1 (en) 2024-02-22 2025-10-02 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025202213A1 (en) 2024-03-26 2025-10-02 Institut National de la Santé et de la Recherche Médicale Lipid nanoparticle loaded with antitumoral agent and functionnalized to target immosuppressive cells
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
CN118638236B (zh) * 2024-07-09 2025-03-14 武汉爱博泰克生物科技有限公司 抗人cd127蛋白的抗体、抗体偶联物及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
EP2032695B1 (en) 2006-05-31 2018-08-15 The Regents of The University of California Cd127 expression inversely correlates with foxp3 and suppressive function of cd4+ tregs
ATE542830T1 (de) 2006-12-04 2012-02-15 Pasteur Institut Als gerüst verwendeter ob-fold zur entwicklung neuer spezifischer bindemittel
UY32038A (es) 2008-08-08 2010-03-26 Glaxo Wellcome Mfg Pte Ltd Inmunoblobulinas anti-cd127 y sus usos
WO2010085643A1 (en) 2009-01-22 2010-07-29 University Of Miami Targeting il-7 signaling as a therapy for multiple sclerosis and other il-7 signaling dependent disorders
UA104663C2 (xx) 2010-01-28 2014-02-25 Глаксо Груп Лимитед Антитіло, що зв'язує cd127$антитело, связывающее cd127
TWI552760B (zh) * 2010-02-24 2016-10-11 雷那特神經科學股份有限公司 拮抗劑抗－ｉｌ－７受體抗體及方法
EP2583980A1 (en) 2011-10-19 2013-04-24 Effimune Antibodies directed against the alpha chain of IL7 receptor - their use for the preparation of drug candidates
EP2955196A1 (en) * 2014-06-10 2015-12-16 Effimune Antibodies directed against CD127
PT3423496T (pt) 2016-02-29 2019-09-05 Ose Immunotherapeutics Anticorpos não antagonistas dirigidos contra a cadeia alfa do domínio extracelular do recetor da il-7 e a utilização do mesmo no tratamento do cancro

Also Published As

Publication number Publication date
US20190382497A1 (en) 2019-12-19
KR20170019417A (ko) 2017-02-21
UA125366C2 (uk) 2022-03-02
AU2015273532A1 (en) 2016-12-22
CL2016003172A1 (es) 2017-07-14
RU2734076C2 (ru) 2020-10-12
MA40202A (fr) 2017-04-19
EP3155014A1 (en) 2017-04-19
PE20170324A1 (es) 2017-04-01
BR112016028755A2 (pt) 2017-11-14
PH12016502445A1 (en) 2017-03-06
IL249449B (en) 2020-06-30
US20170129959A1 (en) 2017-05-11
AU2015273532C1 (en) 2021-07-15
AP2016009599A0 (en) 2016-11-30
KR102612930B1 (ko) 2023-12-13
IL249449A0 (en) 2017-02-28
MX2016016236A (es) 2017-07-05
HK1231487A1 (zh) 2017-12-22
RU2016151265A (ru) 2018-07-18
JP7324565B2 (ja) 2023-08-10
CA2950823A1 (en) 2015-12-17
MX376066B (es) 2025-03-07
US11440964B2 (en) 2022-09-13
EA201692460A1 (ru) 2017-04-28
JP2017522903A (ja) 2017-08-17
CR20160576A (es) 2017-05-08
EA039303B1 (ru) 2022-01-11
CN106715471A (zh) 2017-05-24
AU2015273532B2 (en) 2021-03-04
BR112016028755B1 (pt) 2024-01-16
NZ726932A (en) 2022-02-25
SA516380455B1 (ar) 2020-12-22
TN2016000528A1 (en) 2018-04-04
SG11201610036PA (en) 2016-12-29
EP2955196A1 (en) 2015-12-16
US10428152B2 (en) 2019-10-01
US12371502B2 (en) 2025-07-29
RU2016151265A3 (enExample) 2019-02-08
CN106715471B (zh) 2021-04-09
US20230340133A1 (en) 2023-10-26
JP2021184731A (ja) 2021-12-09
WO2015189302A1 (en) 2015-12-17

Similar Documents

Publication Publication Date Title
PH12016502445A1 (en) Antibodies directed against cd127
SV2018005614A (es) Inhibidores peptidicos del receptor de interleucina 23 y uso para tratar enfermedades inflamatorias
MX2022001086A (es) Anticuerpos e inmunoconjugados del receptor 1 de folato y usos de los mismos.
UA113397C2 (xx) Попередження несприятливих ефектів, спричинених специфічними доменами зв'язування cd3
ZA201605657B (en) Treatment of cancer using anti-cd19 chimeric antigen receptor
EP4378536A3 (en) Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
UA107827C2 (xx) Антитіло до cd40
NZ711946A (en) Newcastle disease viruses and uses thereof
GT201300150A (es) Uso de celulas t modificadas por receptor de antigeno quimerico para tratar cancer
JO3313B1 (ar) التراكيب والطرق لزيادة نمو العضلة
ECSP11011019A (es) Antagonistas del receptor de orexina de isonicotinamida
PH12020552235A1 (en) Anti-cd40 antibodies for use in treating autoimmune disease
CY1118966T1 (el) Νεες συνθεσεις για την προληψη και/ή την θεραπεια εκφυλιστικων διαταραχων του κεντρικου νευρικου συστηματος
EA201390813A1 (ru) Антитела и их применение
UY34116A (es) El anticuerpo neutralizador del receptor de prolactina mat3 y su uso terapéutico
EA201890149A1 (ru) Композиции криопреципитатов и способы их получения
EA201400623A1 (ru) Новые 2h-индазолы в качестве антагонистов рецептора ep
TH171839A (th) แอนติบอดีที่มุ่งต้าน cd127
AR104621A1 (es) TRATAMIENTO DE LA b-TALASEMIA POR EL USO DE TRAMPAS DE LIGANDO ActRII
ECSP10010250A (es) Metodos para el tratamiento de la obesidad y enfermedades y trastornos relacionados con la obesidad
DOP2010000147A (es) Metodos para el tratamiento de la obesidad y enfermedades y trastornos relacionados con la obesidad
HK1228445A1 (en) Treatment of cancer using anti-cd19 chimeric antigen receptor
CR11498A (es) Metodos para el tratamiento de la obesidad y enfermedades y desordenes relacionados a la obesidad
UA102437C2 (ru) Композиции и способы для усиления мышечного роста